• Avanos Medical Inc AVNS.N, AVNS.K is expected to show a rise in quarterly revenue when it reports results on February 26 for the period ending December 31 2024

• The Alpharetta Georgia-based company is expected to report a 2.3% increase in revenue to $177.25 million from $173.3 million a year ago, according to the mean estimate from 2 analysts, based on LSEG data.The company's guidance on October 30 2024, for the period ended December 31, was for revenue between $175.00 million and $180.00 million.

• ​LSEG's mean analyst estimate for Avanos Medical Inc is for earnings of 40 cents per share. The company's EPS guidance on October 30 2024, for the period ended December 31, was between $0.38 and $0.43

• The current average analyst rating on the shares is "hold" and the breakdown of recommendations is no "strong buy" or "buy," 2 "hold" and no "sell" or "strong sell."

• The mean earnings estimate of analysts was unchanged in the last three months. ​

• Wall Street's median 12-month price target for Avanos Medical Inc is $20.00​, above​ its last closing price of $15.45. ​​​

The company's guidance on October 30 2024 for the period ended December 31 was for gross profit margin of USD59%.

This summary was machine generated February 24 at 14:03 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)